Clavulox RTU Injection

The product has a broad spectrum of bactericidal activity against the bacteria commonly found in cattle, dogs and cats. Clinically, this product has been shown to be effective in treating a wide range of diseases in cattle including: respiratory infections, soft tissue infections (eg. joint/navel ill, abscesses, etc), metritis and mastitis. In dogs and cats, Clavulox has proved to be effective in the following conditions: respiratory tract infections, urinary tract infections, skin and soft tissue infections (eg. abscesses, pyoderma, anal sacculitis and gingivitis).

In vitro, this product is active against a wide range of clinically important bacteria including:

Gram positive: Staphylococci (including ß-lactamase producing strains), Streptococci, Corynebacteria, Clostridia,Bacillus anthracis, Actinomyces bovis, Peptostreptococcus spp.

Gram-negative: Escherichia coli (including ß-lactamase producing strains), Salmonellae (including ß-lactamase producing strains). Bordetella bronchiseptica, Campylobacter spp, Klebsiella spp., Proteus spp, Pasteurellae,Fusobacterium necrophorum, Bacteroides (including ß-lactamase producing strains), Haemophilus spp, Moraxella spp. and Actinobacillus lignieresi.

1. Clavulox is a reliable broad spectrum treatment and has an excellent safety profile.
2. Clavulox has been specifically designed for animal use. The novel formulation of Clavulox increases the high cure rates achieved with amoxicillin alone.
3. Clavulox has activity against both gram positive and gram negative aerobes and anaerobes.
4. Clavulanic acid binds to the beta-lactamase enzyme allowing the amoxicillin to kill the bacteria.
5. Clavulox has proven success against mixed bacterial infections in most body tissues.
6. After many years of extensive use in animals, bacterial susceptibility remains high¹.

Resistance to many antibiotics is caused by beta-lactamase enzymes that destroy the antibiotic before it can act on the bacteria themselves. The clavulanate in Clavulox counteracts this defence mechanism by inactivating the beta-lactamases, thus rendering the bacteria sensitive to the rapid bactericidal effect of amoxycillin that occurs at concentrations readily attainable in the body.

Clavulox Ready To Use Injection is a suspension containing 35 mg/mL clavulanic acid as Potassium Clavulanate and 140 mg/mL amoxycillin as Amoxycillin Tihydrate.

Available in 40mL vials. Each mL contains 175mg Clavulox RTU.

Store below 25°C. Do not freeze. Unused product must be discarded 28 days after broaching.

CATTLE, DOGS and CATS: 1mL of suspension per 20kg equivalent to 8.75mg/kg bodyweight. Treatment should be administered once-daily for 3 to 5 days.

Shake the vial to suspend the active material. Inject by the subcutaneous or intramuscular route, then massage the injection site. Injection to be given into the anterior half of the neck in food-producing animals.

The suspension is not suitable for intravenous or intrathecal administration. Care should be taken to avoid contaminating the remaining contents of the vial with water.

In common with all other penicillins, Clavulox should not be used orally or parenterally in rabbits, guinea pigs, hamsters or gerbils, and in all other species for which it is not licensed, including very small herbivores.

May cause allergic reactions or local reaction at the site of injection. Contains amoxycillin, a semi-synthetic penicillin, and has the potential for producing allergic reactions. If an allergic reaction occurs, administer adrenaline and/or corticosteroids. Use of the product may occasionally result in local tissue reaction.

Clavulanic acid is moisture-sensitive. It is very important that a completely dry syringe is used when extracting suspension from the vial in order to avoid contaminating the remaining contents of the vial with drops of water. Contamination will result in obvious beads of dark brown discolouration. Material affected in this way should not be used, as it may have significantly reduced potency.

Penicillins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Do not handle the product if you know you are sensitised to, or if you have been advised not to work with, such preparations. This material may affect the gastrointestinal system if ingested repeatedly in high doses. Handle this product with great care to avoid exposure, taking all recommended precautions including the use of suitable protective gloves.

Withholding Times:

Milk: Milk from treated animals must not be used for human consumption until 36 hours after the last treatment.

Meat: Cattle producing meat and offal for human consumption must not be slaughtered during or within 28 days after the last treatment.

Prescription Animal Remedy. Keep out of reach of children. For animal treatment only.

Zoetis New Zealand Limited. Level 5, 8 Mahuhu Crescent, Auckland 1010, New Zealand. Tel: 0800 650 277, Fax: 0800 628 629. CLAVULOX^® is a registered trade mark of GlaxoSmithKline NZ Ltd. ACVM Registration No. A5722. RVM; Available only under Veterinary Authorisation.

References:

¹Helen Hefferman, Scientist, ESR: Surveillance of Antimicrobial Resistance Among Animal Pathogens In New Zealand, 2001.

For technical enquiries please phone Zoetis Technical Services on 0800 650 277.

• Zoetis Safety Data Sheets
• Label: http://www.foodsafety.govt.nz/